AUTHOR INDEX

Barnes, P. J. 119
Brick, J. 335

Cho-Ming Loi 131

Dufton, M. J. 1

Evenden, J. L. 151

Green, T. P. 309

Hider, R. C. 41

Jordan, V. C. 41

Kirdani, R. Y. 263

Mucklow, J. C. 105

Pertwee, R. G. 189
Pohorecky, L. A. 335

Robinson, S. P. 41
Ryan, C. N. 151

Sandberg, A. A. 263

Tyrer, P. 173

Vestal, R. E. 131

Ward, R. M. 309

AUTHOR INDEX

Barnes, P. J. 119
Brick, J. 335

Cho-Ming Loi 131

Dufton, M. J. 1

Evenden, J. L. 151

Green, T. P. 309

Hider, R. C. 41

Jordan, V. C. 41

Kirdani, R. Y. 263

Mucklow, J. C. 105

Pertwee, R. G. 189
Pohorecky, L. A. 335

Robinson, S. P. 41
Ryan, C. N. 151

Sandberg, A. A. 263

Tyrer, P. 173

Vestal, R. E. 131

Ward, R. M. 309

SUBJECT INDEX

Acetylcholine, ethanol effects 374–76
Adenylate cyclase
  cannabinoid effects 230–34
  ethanol effects 359–61
Adverse effects, fetal drug exposure 320–22
Airways smooth muscle
  and neuropeptides 119–27
  non-adrenergic, non-cholinergic innervation 120
Alcohol and drug metabolism 109 *see also* ethanol
Alcoholism 391, 392
  medical models 393–99 *see also* ethanol, dependence
Aminoglutethimide 60–66
  assay methods 64
  metabolites 62–65
    activity 64
  pharmacokinetics 61–63
  structure 60
Androgen
  in breast cancer therapy 264–69
  cellular mechanisms of action 5
Animal models, developmental pharmacology 328–30
Antiandrogens 85–90
  structures 85, 86
Anticancer agents, steroid-modifying *see* steroid-modifying
Antiestrogens 72–85, 297
  development 72
  structures 73, 74
Aromatase inhibitors 297, 298
Asthma
  axon reflexes 126
  vasointestinal polypeptide 123
ATPase, cannabinoid effects 230

Behavior and psychomotor stimulants 154–65
Benzodiazepines
  choice 181, 182
  dependence 174–76
    potential 177
    predisposing factors 176–79
    prescribing practices 179, 180
  duration 182, 183
  indications for 183–85
Blood circulation, ethanol effects 350–52
Blood pressure, ethanol effects 352, 353
Breast cancer
  androgen metabolism 264–69
  treatment strategies 48

Calcitonin gene-related peptide and airway smooth muscle 125
Cannabinoids, psychotropic
  brain acetylcholine 220–22, 247
  brain binding studies 223–26
  brain dopamine 210–14, 246
    synaptosomal 212, 213
  brain GABA 222, 223, 247–49
  brain histamine 219
  brain 5-HT 214–19, 246
    synaptosomal 217–19
    turnover 215–17
  brain norepinephrine 205–08
    synaptosome 209
    turnover 207, 208
  brain spermidine 219, 220
  delta-9-THC potency 192
  electrophysiology 198–205
    hippocampal evoked potential 200
    sensoricortex evoked potential 200
    spinal reflexes 199
  enzyme effects 226–38
  membrane studies 239–43
  molecular mechanisms 243–46
  monoamine oxidase 226–29
  neuropharmacology 189–251
  paired pulse facilitation 203
  post-tetanic potentiation 202
  psychopharmacological effects 189–94
  solubility 195–98
  structure of components 190
  synapse action 250, 251
  synthetic analogs 193
  therapeutic potential 194
  twitch response 197
Children
  experimental designs 315–19
  and informed consent 314, 315
  multi-institutional studies 319, 320
  pharmacological investigation 309–11
  research, ethics 311–15
Circular dichroism, elapid cytotoxins 10, 11
α-Cobratoxin, α-carbon skeleton 31
Corticosterone, synthetic analogs 275
Cortisol metabolites 277
Cyproterone acetate metabolism 87, 88
Cytotoxins *see also* elapid
  synonyms 1

Danazol 58, 59
Dehydroepiandrosterone, breast cancer 266–68
Dependence
  benzodiazepine use limitation 173–85
  ethanol 391–400
  genetic factors 398
  minor tranquillizers 173–76
Diet and drug metabolism 107, 108
Disease and drug metabolism 110–12
Dopamine, ethanol effects 369–72
Droloxifene metabolism 83, 84
Drug metabolism
  body composition and age 143, 144
  disease 110–12
  elderly 131–45
  environmental factors 105–13
  hepatic model 133–35

interactions 110
liver changes and age 132–43
population studies 106
sex and age 144

Elapid cytotoxins 1–36
amino acid sequences 5–8
assays 33, 34
backbone structure 10, 13
interaction site 32
cell lysis mechanism 19–21
conformation 9–12
–sequence relationships 12–14
evolution 8, 9
hemolysis 18
isolation 1–3
LD_{50} values 26, 27
lyophilization 5
mode of action 15–25
muscle cell interaction 22–25
depolarization 27–30
and α-neurotoxin action 30–32
protein aggregation 21, 22
protein–carbohydrate interaction 17, 18
purification 3–5
structure/activity analysis 25–32
target 34, 35
Elderly, drug metabolism 131–45
Endometrial cancer, steroids 268, 269
Erythrocyte
elapid cytotoxin lysis 25, 27
ion fluxes 21
surface 18
Estradiol
inactivation 273
metabolism 270, 271
Estramustine 284
–binding protein 287
conjugated, properties 294, 295
estrogen conjugate 285–88
mechanisms of action 292–94
metabolic fate 289, 290
non-estrogenic actions 288
sequestration 290–92
Estrogen
conjugates 272
mechanism of cellular action 49
metabolism, cancer treatment 269–75
metabolites of natural 271
synthetic 274
Ethanol
absorption 337
alcoholic drinks 335
dependence 391–400
distribution 337
elimination 338, 339
endocrine effects 382–85
intoxication 341, 342
metabolic role 349, 350
neurochemical effects 353–81
pharmacokinetics 336–39
factors affecting 339–41
pharmacology 335–400
physiological effects 342–53
routes 336
tolerance 385–91
withdrawal 391–400
Ethics, research in children 311–15
Experimental design
analysis 317–19
children 315–19
clinical trial 317
controlled trials 316
Fetal drug exposure
adverse effects 320–22
pattern 322
Flutamide metabolism 88–90

GABA (γ-aminobutyric acid), ethanol effects 376–79
Glucocorticoid in cancer treatment
mechanisms of action 279
metabolism 275–81
role 280, 281
serum binding 279, 280
Gonadotrophin release inhibitors 51–59
non-steroidal 56–58
steroidal 58, 59
structures 58, 59
Guanyl cyclase, ethanol effects 361

Hepatic clearance concept 133–35
Hormone antagonists 47–49
Hormone-dependent cancers, treatment strategies 43–50
4–Hydroxyandrostene–3,17-dione 67
metabolites 70, 72
5-Hydroxytryptamine, ethanol effects 372–74

Ketoconazole
metabolism 69–71
structure 67

LH–RH analogs 51–58
assay 56
clearance 53, 54
development 52, 53
tissues metabolizing 55
Liver, age changes and drug metabolism 132–43
see also hepatic
blood flow 136
drug binding 137, 138
enzyme activities 138–42
enzyme inhibition 142

Medroxyprogesterone acetate metabolism 282–84
Metabolic effects, ethanol 347–49
Monoamine oxidases, cannabinoid effects 226–29
Myocardial effects, ethanol 344–50

Neurochemical effects of ethanol 353–81
acute 354–57
chronic 357–59
Neuropeptides and airway smooth muscle 119–27
Nitrogen mustard, corticoid conjugates 296, 297
Nuclear magnetic resonance, elapid cytotoxins 9, 10
Norepinephrine, ethanol effects 362–69
withdrawal 367, 368

Opiates, ethanol effects 379–82
Organelles, cannabinoid effects 239–43

Peptide histidine isoleucine and airway smooth muscle 124
Pharmacology, developmental 309–30
Phospholipase, cannabinoid effects 234–38
Progestins in cancer treatment 281–84
  metabolites 281
Prostaglandins, cannabinoid effects 236, 237
Psychomotor stimulants
  anorectic effects 162, 163
  asymmetry and rotation 156, 157
  CNS localization 151–67
  cognitive effects 163–65
  conditioned reinforcement 160, 161
  locomotor activity 154–56
  perseveration 159
  rate dependent effects 158
  reinforcement 161, 162
  response distribution 157, 158
  stereotypy 159, 160
  study technique 153, 154

Receptors, estrogen, steroid-binding 263, 264
Renal excretion and age 131, 132
RU23908 metabolism 88–90

Smoking and drug metabolism 109
Steroid, chemotherapeutic agent conjugation 284–99
Steroid hormone
  synthesis root 42
  unusual conjugates 278
Steroid hormone biosynthesis inhibitors 60–72
Steroid-modifying anticancer agents
  metabolism 41–9, 263–99
Steroidogenesis
  adrenal, pathway 47
  blockade 46, 47
  control 43
  ovarian, pathway 45
  regulation, hypothalamopituitary 44
  testicular, pathway 46
Substance P and airway smooth muscle 124, 125

Tamoxifen 74
  assay methods 75, 76
  metabolism 78–80
    activity 80–82
  metabolites 75, 76
  pharmacokinetics 77–79
Teratogenicity
  detection 326
  drug interactions 324
  genetic risk 325
  study problems 322–28
Δ'–Testolactone metabolism 67, 71, 72
Thermoregulation, ethanol effects 342–44
Tolazoline in children 310
Tolerance
  ethanol 385–91
  factors affecting 389–91
  membrane role 388, 389
  stress effects 391
  theories 387
  types 385–87
Toremifene structure and metabolism 82, 83
Trilostane 67–69
  metabolic pathway 68, 69
  structure 67

Vasoactive intestinal polypeptide
  acetylcholine co-transmission 122, 123
  airway smooth muscle effects 121, 122
  asthma 123
  localization 120, 121
  NANC inhibition 122

Withdrawal
  and anxiety 175
  ethanol 367, 371, 391–400
    syndrome 392, 393, 399

Zindoxifine metabolism 84, 85